TET2 and acute myeloid leukemia: It was thought that inhibition of TET2 by mutant IDH is the driver of AML carcinogenesis, but Inoue et al. found significant clinical differences between IDH1 and TET mutant diseases, giving hints of additional mediators in mutant IDH1-induced carcinogenesis [98].